Literature DB >> 29975452

MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a).

Xiao Liang1, Qinghua Zhao2, Tingting Geng2, Shengshu Luo1, Qin He1.   

Abstract

MicroRNAs play vital regulatory roles in various type of tumorigenesis. We aimed to explore the functional microRNAs that might play as therapeutic targets in hepatocellular carcinoma (HCC). In this study, our results revealed that microRNA-106b was significantly increased in HCC tumor tissues. However, miR-106b knockdown remarkably suppressed the growth and increased the apoptosis of Hub-7 HCC cells. Biological analysis indicated that miR-106b directly targeted toZinc finger and BTB domain-containing protein 7A (Zbtb7a) to regulate the apoptosis of Hub-7 cells. Extensively, Zbtb7a overexpression reversed Huh-7 cell apoptosis and growth in vitro. Furthermore, in vivo studies confirmed that miR-106b inhibition or Zbtb7a overexpression retarded the growth of Hub-7 xenograft tumor in nude mice. In conclusion, we provide the evidence for the regulatory role of miR-106b in HCC, which is causally linked to targeting of Zbtb7a. This study may provide miR-106b as a potential therapeutic strategy for HCC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Zbtb7a; apoptosis; hepatocellular carcinoma; miR-106b; tumorigenesis

Mesh:

Substances:

Year:  2018        PMID: 29975452     DOI: 10.1002/jbt.22169

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  9 in total

Review 1.  miR-106b as an emerging therapeutic target in cancer.

Authors:  Surendra Kumar Sagar
Journal:  Genes Dis       Date:  2021-02-12

2.  Long Non-Coding RNA SNHG14 Impedes Viability, Migration and Invasion of Endometrial Carcinoma Cells Through Modulating miR-93-5p/ZBTB7A Axis.

Authors:  Kai Zhang; Yongqin Cai; Qi Zhou; Hong Sun; Jinying Wei
Journal:  Cancer Manag Res       Date:  2020-10-01       Impact factor: 3.989

3.  Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.

Authors:  Weige Tan; Gehao Liang; Xinhua Xie; Wenguo Jiang; Luyuan Tan; Andrew J Sanders; Zihao Liu; Yun Ling; Wenjing Zhong; Zhenluan Tian; Wanyi Lin; Chang Gong
Journal:  Oncologist       Date:  2019-07-12

4.  Breviscapine Participates in the Progression of Prostate Cancer by Inhibiting ZFP91 Expression through Upregulation of MicroRNA-129-5p.

Authors:  Jie Yang; Wanjun Jin; Xiaokang Zhang; Pengcheng Chang; Duo Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-08       Impact factor: 2.629

5.  Retracted Article: Exosome-derived PTENP1 suppresses cisplatin resistance of bladder cancer (BC) by suppressing cell proliferation, migration and inducing apoptosis via the miR-103a/PDCD4 axis.

Authors:  Xingre Lu; Fengyu Chen; Diao Yuan; Xiang He; Xiaowen Liu; Yunju Zi; Yu Lu
Journal:  RSC Adv       Date:  2019-11-19       Impact factor: 4.036

6.  Identification of key miRNAs in the progression of hepatocellular carcinoma using an integrated bioinformatics approach.

Authors:  Qi Zheng; Xiaoyong Wei; Jun Rao; Cuncai Zhou
Journal:  PeerJ       Date:  2020-05-06       Impact factor: 2.984

7.  The miR-372-ZBTB7A Oncogenic Axis Suppresses TRAIL-R2 Associated Drug Sensitivity in Oral Carcinoma.

Authors:  Li-Yin Yeh; Cheng-Chieh Yang; Hsiao-Li Wu; Shou-Yen Kao; Chung-Ji Liu; Yi-Fen Chen; Shu-Chun Lin; Kuo-Wei Chang
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

Review 8.  The multi-faceted functioning portrait of LRF/ZBTB7A.

Authors:  Caterina Constantinou; Magda Spella; Vasiliki Chondrou; George P Patrinos; Adamantia Papachatzopoulou; Argyro Sgourou
Journal:  Hum Genomics       Date:  2019-12-10       Impact factor: 4.639

Review 9.  The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma.

Authors:  Wen-Kuan Huang; Chun-Nan Yeh
Journal:  Biomolecules       Date:  2020-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.